Text size: click to decrease font sizeclick to increase font size (click to alter)
London sarcoma service

Royal National Orthopaedic Hospital NHS Trust

University College London Hospitals NHS Foundation Trust

LSESN logo image

our approach & expertise


research & clinical trials


recently closed trials

AXI-STS - A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and synovial sarcomas. This study is looking at a new drug axitinib, a tablet treatment, for treating soft tissue sarcoma. Axitinib works by blocking the growth of new blood vessels in tumours.

AYAPK - Pharmacokinetics and Pharmacodynamics of Doxorubicin in Children, Adolescents and young adults with Newly Diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma. This trial is looking at differences between how males and females respond to doxorubicin chemotherapy, and whether there is an impact of puberty.

BODiS - Burden of Disease in Sarcoma - this study is running exclusive to UCH/RNOH and will monitor circulating tumour cells in the blood of patients with sarcoma, and investigate whether this technique can be used to monitor how a tumour is responding to treatment.

BRIGHTLIGHT is a National Institute for Health Research (NIHR) funded programme grant evaluating cancer services for young people aged 13 - 24 years in England. Central to this programme of research is the 2012 Teenage and Young Adult (TYA) Cancer Cohort study, which aims to recruit all young people diagnosed with cancer between July 2012 and December 2014 in England. The evaluation of cancer services is through a survey (the BRIGHTLIGHT Survey) and health economic measures, which will be administered to young people five times over three years at 5, 8, 12, 24, and 36 months after diagnosis.

GLU-1 - Double-blind, randomised, cross-over, phase II study, to investigate the efficacy and safety of glucarpidase for routine use after high-dose methotrexate in patients with bone sarcoma. This study is investigating whether using glucarpidase with methotrexate can reduce methotrxate side effects